Enveric Biosciences Granted US Patent #12065404 Today For "C4-CARBOXYLIC ACID-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS USED TO TREAT BRAIN NEUROLOGICAL DISORDERS".
Portfolio Pulse from Benzinga Newsdesk
Enveric Biosciences has been granted a US patent for 'C4-Carboxylic Acid-Substituted Tryptamine Derivatives and Methods Used to Treat Brain Neurological Disorders'. This patent could enhance their intellectual property portfolio and potentially impact their market position in neurological disorder treatments.
August 20, 2024 | 7:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Enveric Biosciences has been granted a US patent for tryptamine derivatives, which could strengthen their position in the treatment of brain neurological disorders.
The granting of a US patent is a significant milestone for Enveric Biosciences as it enhances their intellectual property portfolio. This could lead to increased investor confidence and potential market opportunities in the treatment of neurological disorders, positively impacting their stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100